GIST News

Home/Tag: GIST News

LRG Survey Seeks to Understand Differences in Sutent Dosage Schedules

The Life Raft Group surveyed patients and physicians about dosing options for the drug Sutent (sunitinib) to follow up on a 2011 study that showed that patients on a continuous dose exhibited better clinical outcomes than those on the standard four-week on, two-week off dosing regimen.

By |2019-09-20T13:24:43-04:00January 9th, 2013|News, Sutent|

New gene panel takes mutation testing to a new level

A new gene panel takes mutation testing to a new level. The panel tests for mutations in 23 genes at once will help to properly classify wild-type GIST patients.  Working with next generation sequencing [...]

By |2019-09-20T13:54:43-04:00August 1st, 2012|Mutational Testing, News, Pediatric GIST|

Several GIST clinical trials updated at American Society of Clinical Oncology

By Jim Hughes Here are updates from the American Society of Clinical Oncology conference on three GIST  clinical trials. Panobinostat (HDAC) Phase 1 in 3rd Line GIST: LRG research Team member Sebastian Bauer, MD of Essen University [...]

By |2019-09-20T13:55:31-04:00August 1st, 2012|Clinical Trials, News|
Go to Top